Diagnostics 2013, 3(1), 170-191; doi:10.3390/diagnostics3010170
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
Department of Radiology, University of Minnesota Medical School, MMC 292 Mayo Memorial Building, 420 Delaware Street S.E., Minneapolis, MN 55455, USA
Received: 5 February 2013 / Revised: 1 March 2013 / Accepted: 11 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Molecular Biomarkers for Cancer Targeted Therapeutics)
View Full-Text
|
Download PDF [213 KB, uploaded 15 March 2013]
Abstract
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed. View Full-TextKeywords:
microRNA; replacement therapy; liver cancer; animal model
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Aravalli, R.N. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics 2013, 3, 170-191.
Related Articles
Article Metrics
Comments
[Return to top]
Diagnostics
EISSN 2075-4418
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert